TPG to cut stake in RR Kabel IPO, with potential to quadruple investment returns

| Leave a Comment | IPO

TPG, a US-based private equity investor, is planning to cut its stake in RR Kabel through an initial public offering (IPO). The IPO will allow TPG to sell 11% of its stake in the company, reducing its ownership to 6%.

TPG acquired a 21% stake in RR Kabel in 2018 for an average price of Rs 270.08 per share. The IPO price band is set at Rs 935-1035 per share, with the upper end of the band being nearly four times that of TPG’s initial investment.

This means that if TPG sells all of its shares in the IPO, it could potentially quadruple its investment returns. However, it is worth noting that TPG will be subject to a lock-in period of six months after the listing, during which it will not be able to sell or trade its shares.

The RR Kabel IPO is scheduled to open for subscription on September 13 and will close on September 15. The company is aiming to raise Rs 1,964.01 crore from the IPO, which will be used to repay debt and fund future growth initiatives.

The IPO is being managed by Kotak Mahindra Bank, Morgan Stanley, and Axis Capital.

Here are some key takeaways from the article:

  • TPG is planning to cut its stake in RR Kabel through an IPO.
  • The IPO price band is set at Rs 935-1035 per share.
  • If TPG sells all of its shares in the IPO, it could potentially quadruple its investment returns.
  • The IPO is scheduled to open for subscription on September 13 and will close on September 15.
  • The company is aiming to raise Rs 1,964.01 crore from the IPO.
          

Related News

  • 22 Sep

    Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits

    Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.

  • 22 Sep

    Signature Global IPO Subscribed 11.88 Times on Final Day

    The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.

  • 22 Sep

    Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding

    Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.

  • 22 Sep

    Pharma company Valiant Laboratories to go public on September 27

    Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.

  • 21 Sep

    Unihealth Consultancy makes tepid debut on NSE Emerge

    Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.

Leave a Reply

Your email address will not be published. Required fields are marked *